Filing summary: GlycoMimetics, Inc. Form 10-Q
Entity discrepancy: The request metadata names Crescent BioPharma, Inc., but the supplied filing is for GlycoMimetics, Inc. This summary reflects the filing text provided. Reporting period ended June 30, 2021; filed August 5, 2021. Financial statements are unaudited.
Business context and reporting period
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates. Its lead candidate, uproleselan, is in a Phase 3 trial for relapsed or refractory acute myeloid leukemia (AML). The company has no approved drugs and has not begun commercial operations. Other programs include GMI-1359, preclinical GMI-1687, and early-stage galectin-3 inhibitors.
Key financial metrics
| Metric | Q2 2021 / June 30, 2021 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $142 for Q2; $1.06 million for the first six months | Q2 2020: $0; first six months 2020: $9.0 million |
| Net loss | $14.40 million for Q2; $28.67 million for the first six months | Q2 2020: $14.08 million; first six months 2020: $21.74 million |
| Research and development expense | $10.17 million for Q2; $21.31 million for the first six months | Q2 2020: $9.87 million; first six months 2020: $22.54 million |
| General and administrative expense | $4.24 million for Q2; $8.43 million for the first six months | Q2 2020: $4.23 million; first six months 2020: $8.67 million |
| Cash and cash equivalents | $118.85 million | $137.04 million at December 31, 2020 |
| Net cash used in operating activities | $27.74 million for the first six months | $18.05 million for the first six months of 2020 |
| Total liabilities | $12.09 million, including $2.38 million of lease liabilities | $14.61 million at December 31, 2020 |
The filing reports no material interest-rate sensitivity from a 100-basis-point move. No conventional revenue or profit margin is meaningful for this pre-commercial company. The Q2 revenue is reported as $142 in the financial statements; management’s discussion rounds Q2 revenue to zero in thousands.
Material changes versus comparable periods
- First-half revenue declined by $7.94 million, from $9.0 million to $1.06 million. The 2020 amount was the upfront payment under the Apollomics agreement; 2021 revenue primarily reflects clinical-supply sales to Apollomics.
- First-half net loss increased by $6.93 million despite total costs and expenses declining by 5%, as the prior-year upfront license revenue did not recur and interest income fell substantially.
- First-half operating cash use rose by $9.68 million year over year. Cash declined by $18.18 million from year-end 2020, partly offset by $9.56 million of net proceeds from common-stock sales.
- First-half R&D expense decreased 5%, primarily because manufacturing and formulation costs declined, partly offset by higher uproleselan clinical-trial costs. Q2 R&D expense increased 3% year over year as trial enrollment and clinical costs rose.
- Common shares outstanding increased from 49.02 million at year-end 2020 to 51.54 million at June 30, 2021, principally reflecting ATM sales.
Outlook, commentary, risks and contingencies
- Management estimated that cash and cash equivalents would fund operating expenses and capital requirements into the fourth quarter of 2022. The notes separately say available funds should cover operations for at least 12 months from the filing date. These are estimates based on assumptions and may prove wrong.
- Management expected to complete enrollment in the approximately 380-patient global Phase 3 uproleselan trial by year-end 2021. COVID-19 previously slowed site initiation and enrollment; enrollment had returned to forecast levels, but fluctuating infection rates could cause renewed disruption.
- Two investigator-sponsored uproleselan studies began dosing in July 2021; preliminary or interim data were expected in 2022. A separate IST begun in May 2021 was also expected to provide a data readout in 2022.
- The Apollomics agreement covers Greater China rights to uproleselan and GMI-1687. GlycoMimetics may receive up to approximately $179 million in further development and commercial milestones plus tiered royalties, but achievement and timing are uncertain. The company received a $1 million development milestone in 2020 and recognized $1.1 million of clinical-supply revenue in the first half of 2021.
- The company expects continued operating losses and negative operating cash flows, and may need additional capital. Equity financing could dilute shareholders; financing may be unavailable on acceptable terms. The ATM agreement had approximately $86.3 million of capacity remaining at June 30, 2021.
- Material development risks include clinical-trial enrollment and outcomes, regulatory approval, manufacturing, commercialization, reimbursement, competition, and access to financing. The company reported no material legal proceedings and no material change to the risk factors from its 2020 Form 10-K.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing is GlycoMimetics, not Crescent BioPharma.
- Track Phase 3 uproleselan enrollment and timing, including any COVID-19 effects, and assess whether year-end 2021 enrollment expectations were achieved.
- Reconcile cash runway assumptions with quarterly operating cash burn and any later financing activity.
- Monitor clinical progress and milestone or royalty prospects under the Apollomics agreement; these payments are conditional and not assured.
- Assess dilution from ATM and other equity sales, including subsequent share counts and remaining sales capacity.